Know Cancer

or
forgot password

The Healthy Elderly Longevity Cohort


N/A
80 Years
N/A
Open (Enrolling)
Both
Healthy

Thank you

Trial Information

The Healthy Elderly Longevity Cohort


Inclusion Criteria:



1. Age 80 years or older

2. Eligible for blood draw and/or saliva collection

3. Be reliable, cooperative and willing to comply with all protocol-specified procedures

4. Able to understand and grant informed consent

5. Be healthy or have mild medical conditions that may be associated with the normal
aging process, including:

- Hypertension, well controlled (no more than 3 medications)

- Osteoporosis, Osteopenia and/or osteoarthritis

- Benign prostatic hypertrophy

- Cataracts, Glaucoma, Macular Degeneration

- Dyslipidemia

- Hypothyroidism

- Pre-diabetes/impaired fasting glucose (fasting blood glucose 100-126 mg/dL, if
known)

Exclusion Criteria:

1. < 80 years old

2. Participants have been previously enrolled in The Scripps Genebank Healthy Elderly
Cohort

3. Treatment with any investigational agents or devices within thirty days preceding
enrollment in the study.

4. Self-reported history or current diagnosis of significant chronic conditions
including:

- Any Cancer (including polycythemia; excluding basal or squamous cell skin
cancer).

- Coronary Artery Disease/Myocardial Infarction

- Stroke/TIA

- Deep Vein Thrombosis/Pulmonary Embolus

- Chronic Renal Disease/Hemodialysis

- Significant Auto-immune/Inflammatory conditions such as (Rheumatoid Arthritis,
Lupus, Crohn's, etc.

- Alzheimer's/Parkinson's

- Diabetes (Hemoglobin A1C > 6.5 % or fasting glucose >126 mg/dL or treated with
oral diabetic medication or insulin if known)

- Aortic or Cerebral Aneurysm

5. Currently taking any of the following medications on a regular basis:

- Oral chemotherapeutic agents (ex.: tamoxifen, doxorubicin, mitoxantrone,
bleomycin)

- Anti-platelet agents, not including aspirin (ex.: clopidogrel/plavix,
dipyridamole/aggrenox/persantine, ticlopidine/ticlid)

- Cholinesterase inhibitor for Alzheimer's disease (i.e. donepezil/Aricept)

- Insulin

6. Subject has a significant medical condition which, in the Investigator's opinion, may
interfere with the patient's optimal participation in the study or would potentially
confound interpretation of the individual's phenotype.

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Biorepository Creation

Outcome Description:

Create a biorepository from participants' blood and/or saliva donations we will ultimately be able to define genes for various diseases and understand health

Outcome Time Frame:

ten years

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

HSC 07-4789

NCT ID:

NCT01004133

Start Date:

August 2007

Completion Date:

January 2020

Related Keywords:

  • Healthy
  • Age 80 or older
  • No chronic disease

Name

Location

Scripps Translational Science InstituteLa Jolla, California  92037